कंपनी का अवलोकन
Legend Biotech Corporation operates as a specialized biopharmaceutical entity focused on the discovery, development, manufacturing, and commercialization of novel cell therapies primarily for oncology and other indications across the United States, China, and Europe. The company functions within the broader Healthcare sector, specifically navigating the complex Biotechnology industry where innovation in cell-based treatments defines its strategic landscape. In terms of scale, the organization employs approximately 2,900 individuals and holds a market capitalization of $3.37 billion. This market valuation, combined with annual revenue of $1.03 billion, indicates that the company has established a significant foothold in the biopharmaceutical market, positioning it as a substantial player capable of funding extensive research and development programs while maintaining a substantial workforce to support its global operations.
वित्तीय स्वास्थ्य
The company reported total revenue of $1.03 billion over the trailing twelve months, yet it recorded a net income loss of $296.8 million and an EBITDA of -$127.1 million. The substantial gap between the $1.03 billion in revenue and the -$296.8 million net income reveals a cost structure characterized by high operating expenses typical of the biotechnology sector, where research, development, and manufacturing costs significantly outpace immediate profitability. Free cash flow stands at -$133.987504 million, indicating that the company is currently burning cash to fuel its growth initiatives rather than generating surplus liquidity for immediate distribution or debt reduction. This negative free cash flow suggests the company relies on external capital sources to maintain financial flexibility during its expansion phase. Analyzing the three key margins shows a gross margin of 20.0%, an operating margin of -6.7%, and a profit margin of -28.8%, which collectively indicate that while the company retains a portion of sales revenue after direct costs, it struggles to cover overheads and achieve overall profitability. The balance sheet displays $948.60 million in cash against $413.70 million in debt, resulting in a debt-to-equity ratio of 41.28, which suggests a leveraged position where cash reserves comfortably exceed total liabilities. Furthermore, a current ratio of 1.96 indicates strong short-term liquidity, implying the company possesses ample current assets to cover its short-term obligations without immediate distress. Return on Equity is recorded at -29.1% and Return on Assets at -5.0%, metrics that reveal the company is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a common characteristic for biotech firms in early commercialization phases.
मूल्यांकन आकलन
Legend Biotech Corporation does not have a trailing P/E ratio as earnings are negative, but it trades with a forward P/E of 15.83, which implies the market is pricing in an expectation of future earnings recovery or stabilization. The price-to-book ratio stands at 3.36, indicating that the stock is trading at a significant premium above its net book value, reflecting high market expectations for the potential success of its pipeline. Additionally, the price-to-sales ratio is 3.27 and the EV/EBITDA is -48.76, suggesting that valuation is being driven by revenue growth potential rather than current earnings power or traditional multiple expansion. The stock's trading range over the past year spans from a 52-week low of $16.24 to a 52-week high of $45.30, providing a wide band of volatility for investors to analyze relative entry and exit points. The beta value of 0.08 indicates that the stock's price movements are extremely low in correlation to the broader market, suggesting it behaves as a distinct asset class with unique drivers rather than following general market trends.
Growth & Income
The company demonstrated a robust revenue growth rate of 64.2% year-over-year, whereas earnings growth is not applicable due to current losses, implying that top-line expansion is outpacing profitability, a standard trajectory for companies scaling commercial operations. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a strategy of reinvesting all generated earnings back into research, development, and manufacturing to accelerate product pipelines. This approach prioritizes long-term market capture and asset accumulation over immediate income generation for shareholders. Overall, the growth and income profile is defined by aggressive top-line expansion and zero dividend distribution, characteristic of a capital-intensive biotechnology firm focused on future commercialization milestones rather than current shareholder yield.